Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

60;

ANA773

  • Planned Phase IIa Study – In late 2010 the Company announced plans to resume development of ANA773 in HCV as a complement to DAAs in potential all oral regimens. The next planned study is a 28-day study of ANA773, in combination with ribavirin in the first cohorts and as triple therapy in combination with ribavirin and a DAA in subsequent cohorts. Anadys intends to conduct this Phase IIa study of ANA773 in Europe and expects that up to approximately 75 patients will participate in the trial, inclusive of the DAA cohorts.  ANA773 is the Company's oral, small-molecule inducer of endogenous interferons that acts via the TLR7 pathway.
  • 2011 Anticipated Milestones – Anadys intends to commence the ANA773 28-day study during the second quarter of 2011 and expects to receive 4 week viral load data for ANA773 plus ribavirin in the fourth quarter of 2011.

  • Financial Results and HighlightsAs of December 31, 2010, Anadys' cash, cash equivalents and securities available-for-sale totaled $38.0 million compared to $20.5 million as of December 31, 2009.  The increase in cash, cash equivalents and securities available-for-sale reflects the receipt of net proceeds of $34.7 million from the Company's completed equity financings in June and October of 2010, partially offset by the Company's cash utilization during the year to fund operations.

    Total operating expenses were $4.5 million for the fourth quarter of 2010, compared to $5.6 million for the fourth quarter of 2009.  Included as a component of operating expenses were non-cash, share-based expenses of $0.3 million and $0.4 million for the fourth quarter of 2010 and 2009, respectively.

    Research and development expenses were $2.8 million for the fourth quarter of 2010, compared to $4.0 million for the fourth quarter of 2009.  Included as an offset to research and development expenses in the fourth quarter of
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
    (Date:1/14/2014)... January 14, 2014 During the 1600’s through ... as “The Doctor’s Plague.” In this time period, doctors did ... led, at times, to the death of vulnerable patients. In ... know that they may be unwittingly transmitting herpes viruses to ...
    (Date:1/14/2014)... NC (PRWEB) January 14, 2014 BioMedomics, ... on ultra-sensitive POC diagnostic platforms and novel disease specific POC ... round of financing netting a total of $690,000. The investment ... capital in the company. This group of private investors has ...
    (Date:1/14/2014)... Panama (PRWEB) January 14, 2014 ... received the county’s first clinical trial approval for ... cord-derived mesenchymal stem cells (MSC) from the Comité ... Board (IRB). , Rheumatoid Arthritis (RA) is an ...
    Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
    ... , , CALGARY, Dec. ... company developing protein pharmaceuticals in crop plants, today announced ... of its plant-produced insulin with the first injection of ... the United Kingdom (UK), will include up to 30 ...
    ... numerous,shareholder inquiries, CEL-SCI Corporation (NYSE Alternext US: CVM) announced,today ... manufacturing facility to,its website. The pictures can be accessed ... link "Updated Pictures of,Manufacturing Facility" in the special highlights ... is developing its cancer product Multikine(R) for approval as ...
    ... FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a biopharmaceutical ... cardiovascular disease, inflammatory disease,and cancer, today announced that ... that inhibit spleen tyrosine kinase (Syk) and its ... at the annual meeting of the,American Society of ...
    Cached Biology Technology:SemBioSys begins phase I/II trial of insulin produced in plant seeds 2SemBioSys begins phase I/II trial of insulin produced in plant seeds 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3
    (Date:4/18/2014)... as they,re planted may be good news for a garden. ... wild, a plant whose seeds sprouted at the first ,warm ... an insurance policy against late frosts or unexpected dry spells, ... Plants whose seeds put off sprouting until conditions are ... team of researchers working at the National Evolutionary Synthesis Center ...
    (Date:4/17/2014)... peptide inhibits RSV infection , Respiratory syncytial ... respiratory tract infections, generating life-threating illness in very ... therapies are limited. RSV enters host cells through ... six-helix fusogenic bundle. Small interfering peptides that prevent ... these peptides are highly susceptible to degradation. In ...
    (Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
    Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
    ... came from other planets. So concludes a major scientific article which ... Cosmology.com For thousands ... life. Surprisingly, most scientists and the Catholic Church are of the ... "organic soup." In the Judeo-Christian Bible, the ...
    ... Dental and tissue engineering researchers at Tufts University School of ... at Tufts have harnessed the pluripotency of human embryonic stem ... skin and the oral mucosa (the moist tissue that lines ... online in advance of print in Tissue Engineering Part ...
    ... scientists at Iowa State University,s Plant Sciences Institute has ... in plant genes much more efficient, practical and safe. ... associate scientist, and Jeffery Townsend, an assistant scientist, and ... have a huge impact on plant genetic work in ...
    Cached Biology News:Life on Earth came from other planets 2Life on Earth came from other planets 3Life on Earth came from other planets 4Skin-like tissue developed from human embryonic stem cells 2Iowa State University researchers develop process for 'surgical' genetic changes 2Iowa State University researchers develop process for 'surgical' genetic changes 3
    ...
    ...
    ...
    ... Sepharose High Performance, 5 ml. The ... in HiTrap Streptavidin columns for fast, ... packing into Tricorn 5/50 GL, XK ... scale purifications are required.Extremely useful for ...
    Biology Products: